Bleeding Rates with Long-Term Combination Therapy in Selected Clinical Trials
| Trial | Patient Population | Duration (months) | Major and Minor Bleeds | |
|---|---|---|---|---|
| Combination Therapy (%) | Monotherapy (%) | |||
| CURE (9) | NSTEMI | 9 | 8.8 | 5.1 |
| CREDO (11) | PCI | 12 | 14.1 | 12.3 |
| CHARISMA (3) | CAD | 28 | 3.8 | 2.6 |
| MATCH (5) | CVA | 18 | 5.1 | 1.6* |
| TRITON (2) | ACS with PCI | 15 | 5.0†/3.8 | NA |
* Clopidogrel monotherapy.
† Prasugrel plus aspirin.
CURE, Clopidogrel in Unstable Angina to Prevent Recurrent Events; CREDO, Clopidogrel for the Reduction of Events During Observation; CHARISMA, Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance; MATCH, Management of Atherothrombosis with Clopidogrel in High-Risk Patients; TRITON, Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel; NSTEMI, non-ST-segment elevation myocardial infarction; CAD, coronary artery disease; CVA, cardiovascular accident; ACS, acute coronary syndrome; PCI, percutaneous coronary intervention.